We're in the midst of an 'Imax awakening,' CEO says. How the company makes millions

Imax’s Christopher Nolan-driven summer slate translated into a major box-office spike: July became Imax’s highest-grossing month ever with $257M in gross global box office, and “The Odyssey” reached $289M globally (biggest Imax release ever) within less than a month. Imax says it typically earns 12.5% of Imax box office under its “content solutions” deals (vs. ~$151M revenue in 2025) and about $251M last year from technology licensing/leases, supported by premium pricing (Imax 70mm tickets ~ $27.77 vs. ~$16.30 standard). With ticketing crashes ahead of “Dune: Part Three” (Dec. 18) and only 25 Imax 70mm theaters in the U.S. (41 worldwide), the news reinforces strong consumer willingness to pay for premium format experiences.

Analysis

The real read-through is not “movie demand is strong,” but that premium-format scarcity is becoming a monetization moat. IMAX captures both sides of the value chain: higher rev-share on event titles and a licensing/installation stream that is relatively insensitive to near-term attendance, so a strong slate can lift both revenue and mix at the same time. The important second-order effect is that every successful event film makes IMAX more valuable to studios and exhibitors, which should support future screen additions without IMAX having to fund a full theater footprint.

Competitive pressure is likely to hit the adjacent premium layers first, not standard exhibition. Dolby Cinema and Regal RPX are more vulnerable if consumers increasingly treat “premium large format” as a destination category, but the bigger economic winner may be the exhibitors that can selectively command higher ticket pricing without taking full tech risk. For AMC/CNK-type operators, the upside is mix, not volume; however, IMAX has better bargaining power because it owns the format brand and the scarce premium supply.

The catalyst path is months, not days: the next major tentpoles will test whether this is a one-off halo or a durable demand shift. The contrarian risk is that the market extrapolates a culturally resonant title into a structural step-up in utilization, when the category is still hit-driven and capacity constrained. If the next two premium releases underwhelm on occupancy or the installation pipeline fails to inflect, the multiple can compress quickly because the market is likely paying for a sustained growth story, not just a strong quarter.

Key Decisions for Investors

• Long IMAX on any post-event-film pullback; thesis is mix expansion plus higher rev-share durability over the next 1-3 quarters, with downside limited unless the premium slate disappoints.
• Pair trade: long IMAX / short AMC or CNK over the next 1-3 months if you want the cleaner economics of format ownership versus exhibitor capex and operating leverage; IMAX should retain more margin per incremental premium dollar.
• Use call spreads in IMAX into the next major release window rather than outright stock if the move has already re-rated; the trade is a slate/catalyst expression with defined downside if ticket demand normalizes.
• Watch the next two premium title box-office prints and IMAX installation commentary; if occupancy/mix slips or management does not raise forward installation expectations, reduce exposure because the ‘awakening’ narrative is likely priced in.